

Cambridge University Press

978-1-107-02286-7 - A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs

D. G. Cunningham Owens

Frontmatter

[More information](#)

---

# A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs

---

Cambridge University Press  
978-1-107-02286-7 - A Guide to the Extrapyrimal Side-Effects of Antipsychotic Drugs  
D. G. Cunningham Owens  
Frontmatter  
[More information](#)

Cambridge University Press  
978-1-107-02286-7 - A Guide to the Extrapyrarnidal Side-Effects of Antipsychotic Drugs  
D. G. Cunningham Owens  
Frontmatter  
[More information](#)

---

# A Guide to the Extrapyrarnidal Side-Effects of Antipsychotic Drugs

---

**D. G. Cunningham Owens**

Professor of Clinical Psychiatry, University of Edinburgh, Division of Psychiatry, Royal Edinburgh Hospital, Edinburgh, UK



Cambridge University Press  
978-1-107-02286-7 - A Guide to the Extrapyrarnidal Side-Effects of Antipsychotic Drugs  
D. G. Cunningham Owens  
Frontmatter  
[More information](#)

CAMBRIDGE  
UNIVERSITY PRESS

University Printing House, Cambridge CB2 8BS, United Kingdom  
Published in the United States of America by Cambridge University Press, New York  
Cambridge University Press is part of the University of Cambridge.  
It furthers the University’s mission by disseminating knowledge in the pursuit of  
education, learning and research at the highest international levels of excellence.

[www.cambridge.org](http://www.cambridge.org)  
Information on this title: [www.cambridge.org/9781107022867](http://www.cambridge.org/9781107022867)

© D. G. Cunningham Owens 2014

This publication is in copyright. Subject to statutory exception  
and to the provisions of relevant collective licensing agreements,  
no reproduction of any part may take place without the written  
permission of Cambridge University Press.

First edition first published 1999  
Second edition first published 2014

Printed in the United Kingdom by Bell and Bain Ltd

*A catalogue record for this publication is available from the British Library*

*Library of Congress Cataloguing in Publication data*

Owens, D. G. Cunningham (David Griffith Cunningham), 1949– author.  
A guide to the extrapyramidal side-effects of antipsychotic drugs / D. G. Cunningham Owens. – Second edition.  
p. ; cm.

Includes bibliographical references and index.  
ISBN 978-1-107-02286-7 (hardback)

I. Title.  
[DNLM: 1. Basal Ganglia Diseases--chemically induced. 2. Antipsychotic Agents--adverse  
effects. 3. Extrapyrarnidal Tracts--drug effects. 4. Neurotoxicity Syndromes. WL 307]  
RM333.5  
615.7’882--dc23 2013039676

ISBN 978-1-107-02286-7 Hardback

Cambridge University Press has no responsibility for the persistence or accuracy of  
URLs for external or third-party internet websites referred to in this publication,  
and does not guarantee that any content on such websites is, or will remain,  
accurate or appropriate.

.....  
Every effort has been made in preparing this book to provide accurate and up-to-date information which is in accord with  
accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort  
has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors and publishers can  
make no warranties that the information contained herein is totally free from error, not least because clinical standards are  
constantly changing through research and regulation. The author, editors and publishers therefore disclaim all liability for  
direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay  
careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

# Contents

*Preface to the second edition*   vii

## Part 1 – Setting the scene

- 1   **The origins of psychopharma**   1
- 2   **Some preliminaries**   13

## Part 2 – The syndromes

- 3   **Acute dystonias**   35
- 4   **Parkinsonism**   68
- 5   **Akathisia**   134
- 6   **Tardive dyskinesia**   169

## Part 3 – Particular issues

- 7   **Tardive and chronic dystonia**   225
- 8   **Special populations**   246

## Part 4 – Assessment

- 9   **The clinical examination**   265
- 10 **An overview of some standardised recording instruments**   276

## Part 5 – Matters arising

- 11 **Involuntary movements and schizophrenia: a limitation to the concept of tardive dyskinesia?**   295
- 12 **And finally ... the salutary tale of ‘atypicality’**   304

*References*   320  
*Index*   371

Cambridge University Press  
978-1-107-02286-7 - A Guide to the Extrapryamidal Side-Effects of Antipsychotic Drugs  
D. G. Cunningham Owens  
Frontmatter  
[More information](#)

## Preface to the second edition

To wait fifteen years for the second edition of any text-book does not speak of the unbridled success of the first. In fact, for a specialist piece in a circumscribed area, the first edition on the present subject did, from the author's perspective at least, gratifyingly well, both in terms of reviews and sales. There is, however, little reward in devoting the effort required to produce a work of this sort (especially when, in academic appraisal terms, books hardly register compared to original research) if fashion has turned against one's topic.

For the past decade, the extrapyramidal side-effects (EPS) of antipsychotic drugs have certainly been out of fashion – up there with flared jeans and disco music. Definitely not cool! With the age of 'atypicality', metabolic issues assumed an ascendancy in the literature that mirrored the decline in EPS. And why should the average practitioner view EPS as anything other than historical exotica when airport departure lounges were clogged with opinion leaders flying the world to spread just that message? A second edition seemed hard to justify.

I was, once upon a time, one of those 'opinion leaders', presenting an upbeat optimism on the subject of EPS tolerability with the new, exciting 'atypical' drugs – until, that is, I became increasingly concerned that the message I was conveying to my colleagues was not entirely consonant with the one my patients were imparting to me. EPS may have slipped beneath consideration elsewhere on the planet, but in the City of Edinburgh, they still seemed to show themselves with brazen disregard to whether antipsychotic choices were 'typical' or 'atypical'. It is true that the bent and shuffling 'old folk' in their twenties who formed the backdrop to my early years in psychiatry seemed to have melted away – but was this novel pharmacology or more prudent therapeutics? Looking beyond the marketing blurbs, it became as hard to see the pharmacological revolution as it was to ignore the intrusive shades of long-time neurological companions.

EPS have not gone away. Of course, the original efficacy studies for newer antipsychotics never claimed they would – only that the liability seemed to be reduced. But over the past few years, a number of pragmatic effectiveness studies have shaken even that assertion. The fact is that EPS are alive and well and living within the profiles of all currently available antipsychotic compounds (and a number of other drug types besides). Indeed, there is an argument presented in the present volume that so long as dopamine antagonism is the target 'anti-psychosis' action, they may to some extent be inevitable. It just depends on how wide you draw the boundaries and how closely you are prepared to look.

So it is time to raise the standard once again and come out fighting to nudge and jostle EPS back to their rightful position at the centre of risk–benefit appraisals for the use of antipsychotic drugs, and hence as issues of paramount importance to all those who prescribe and monitor these, and other, compounds that disrupt nigrostriatal dopamine function. This is nowadays a sizeable constituency. It is not just psychiatrists who need to be alert, but neurologists, primary care physicians, gastroenterologists, geriatricians and those involved in emergency medicine and intensive care, plus a wide range of non-medical professionals, such as community nurses and pharmacists who monitor, and in some countries also themselves prescribe, such compounds.

Second editions usually involve a degree of updating, little more. The present work has, however, been substantially (>80%) rewritten. A decade and a half is a long time in medical research and would, in itself, justify more than mere tinkering. What is striking, however, is the change in the landscape available for review now, compared to the late 1990s. Over the past decade or two, basic research on EPS has shrunk to a trickle compared to its heyday in the 1980s and early 1990s, with psychiatry contributing just the occasional splash. This can only have come from a genuine belief that the

Preface to the second edition

problem was over, the risks ameliorated. If so, it is ironical that such evaporation of interest should take place when so much has been happening in movement disorders in general, for there was a time when the two were inextricable – research in the drug domain feeding into research on idiopathic disorders, and vice versa. It is less the new material we have on EPS that justifies a rewrite than this expansion on the neurological front, which brings large cuts of comparative meat to the table to be pondered.

In addition, however, the original version of the present work adopted an overwhelmingly clinical approach – an ‘in-my-experience’ and ‘here-is-the-evidence’ approach. In these days of evidence-based medicine and readerships raised on it, this is less than acceptable. So the emphasis is inverted this time round – to ‘here-is-the-evidence’ and ‘in my experience’ – though one must admit that the guidance and recommendations – indeed, the literature itself – remain firmly filtered through my own clinical experience. Experience, of course, means little if it has not translated into that most precious of medical commodities, expertise – that little ‘extra’ the years of experience offer one the opportunity to accrue. So it is my hope that four decades of clinical experience burnish, rather than dull, the facts.

Evidence-based practice exerts a further pull, for it fundamentally challenges what exactly a ‘textbook’

should be. Facts are clearly important but in a world where all facts are available at the click of a mouse, more is now demanded. In addition to facts, the present work aims to provide some degree of context in, for example, the historical frame of reference in which antipsychotic drugs came to us, and in comparisons and contrasts with comparable neurological disorders. But neither do we shy away from controversies that still exist – indeed, are perhaps flourishing in an environment where ‘atypical’ has become part of the psychopharmacological vernacular, yet looks increasingly frail and insubstantial. With regard to the opinion presented in relation to these controversies the reader may not agree with everything in the following pages, but I will be content if sufficient has been presented to inform his or her indignation.

Finally, one should never be loath to acknowledge the role one’s teachers played in honing that expertise and it is a pleasure to record the debt I owe to all the many hundreds of patients who, over a now rather long career, have allowed me to learn from their misfortunes, and to the late Professor David Marsden, whose charismatic teaching style I have, through these years, tried but so often failed, to emulate. It is also a pleasure to offer gratitude to my long-standing friend and colleague, Professor Eve Johnstone, for her invaluable comments on various drafts of this work.